Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice

Oliver Semler, Valérie Cormier-Daire, Ekkehart Lausch, Michael B. Bober, Ricki Carroll, Sérgio B. Sousa, David Deyle, Maha Faden, Gabriele Hartmann, Aaron J. Huser, Janet M. Legare, Klaus Mohnike, Tilman R. Rohrer, Frank Rutsch, Pamela Smith, Andre M. Travessa, Angela Verardo, Klane K. White, William R. Wilcox, Julie Hoover-Fong

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Introduction: Vosoritide is the first precision medical therapy approved to increase growth velocity in children with achondroplasia. Sharing early prescribing experiences across different regions could provide a framework for developing practical guidance for the real-world use of vosoritide. Methods: Two meetings were held to gather insight and early experience from experts in Europe, the Middle East, and the USA. The group comprised geneticists, pediatric endocrinologists, pediatricians, and orthopedic surgeons. Current practices and considerations for vosoritide were discussed, including administration practicalities, assessments, and how to manage expectations. Results: A crucial step in the management of achondroplasia is to determine if adequate multidisciplinary support is in place. Training for families is essential, including practical information on administration of vosoritide, and how to recognize and manage injection-site reactions. Advocated techniques include establishing a routine, empowering patients by allowing them to choose injection sites, and managing pain. Patients may discontinue vosoritide if they cannot tolerate daily injections or are invited to participate in a clinical trial. Clinicians in Europe and the Middle East emphasized the importance of assessing adherence to daily injections, as non-adherence may impact response and reimbursement. Protocols for monitoring patients receiving vosoritide may be influenced by regional differences in reimbursement and healthcare systems. Core assessments may include pubertal staging, anthropometry, radiography to confirm open physes, the review of adverse events, and discussion of concomitant or new medications—but timing of these assessments may also differ regionally and vary across institutions. Patients and families should be informed that response to vosoritide can vary in both magnitude and timing. Keeping families informed regarding vosoritide clinical trial data is encouraged. Conclusion: The early real-world experience with vosoritide is generally positive. Sharing these insights is important to increase understanding of the practicalities of treatment with vosoritide in the clinical setting.

Original languageEnglish
Pages (from-to)198-214
Number of pages17
JournalAdvances in Therapy
Volume41
Issue number1
DOIs
StatePublished - Jan 2024

Keywords

  • Achondroplasia
  • Assessments
  • Clinical practice
  • Early experience
  • Guidance
  • Management
  • Monitoring
  • Practicalities
  • Vosoritide

Fingerprint

Dive into the research topics of 'Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice'. Together they form a unique fingerprint.

Cite this